Curated News
By: NewsRamp Editorial Staff
August 12, 2026
Volition's Lateral Flow Sepsis Test Shows High Correlation with Lab Assay
TLDR
- VolitionRx's lateral flow sepsis test matches lab accuracy, enabling rapid bedside use and market expansion beyond central labs.
- VolitionRx's lateral flow prototype showed high correlation (Spearman 0.85, Pearson 0.881) with its automated Nu.Q NETs test in sepsis patients.
- This rapid, point-of-care test could save lives by enabling quicker sepsis identification in emergency settings, improving patient outcomes globally.
- A finger-prick test for sepsis is now possible, matching lab accuracy and bringing testing to bedside, clinics, and homes.
Impact - Why it Matters
This news matters because it could revolutionize sepsis management by enabling rapid, point-of-care testing, potentially saving lives through earlier intervention and expanding access to critical diagnostics in resource-limited settings.
Summary
VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, has announced that its lateral flow finger-prick prototype for sepsis testing showed high correlation with its established automated Nu.Q NETs test in critically ill patients. The findings, presented as part of the SUMMIT program, revealed a Spearman correlation of 0.85 and Pearson correlation of 0.881 compared with the CE-marked laboratory assay, indicating that the rapid test could be a reliable alternative for decentralized settings.
The study evaluated capillary blood and plasma samples from intensive care patients, demonstrating that the lateral flow format could enable faster clinical decision-making and broaden testing to emergency rooms, doctors' offices, intensive care units, and potentially even home use. This is particularly significant for expanding access to nucleosome testing in countries with limited centralized laboratory infrastructure, potentially improving outcomes for sepsis patients worldwide. The company highlighted that the decentralized format could facilitate earlier identification of high-risk patients, aligning with its mission to save lives through earlier detection and monitoring of life-altering diseases.
Volition, which focuses on advancing the science of epigenetics, develops simple and cost-effective blood tests for detecting and monitoring diseases like sepsis and certain cancers. Its research and development activities are centered in Belgium, with additional offices in the U.S. and London. The full press release is available at https://ibn.fm/81Vlm. For more about Volition, visit Volition. The news was disseminated by BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Volition's Lateral Flow Sepsis Test Shows High Correlation with Lab Assay
